and Item 7.01, including Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

General Counsel — Courtney Nelson Wills: The Senior Vice President, General Counsel, and Corporate Secretary is resigning for personal reasons with a planned transition period, representing a genuine loss of a senior officer but not a sudden or negative shock.

Director — David Endicott, Linnea Burman: The filing discloses the appointment of two new independent directors to fill vacancies created by a board size increase, which is a routine governance action rather than an executive departure.

and Item 7.01, including Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Director — Brett Wall: The filing reports the resignation of a parent-company nominated director due to his internal role change at Medtronic, with an immediate appointment of a successor, indicating an orderly and routine board succession rather than a loss of senior executive management.

Regulation FD Disclosure On April 24, 2026, Medtronic plc (“Medtronic”), the parent company of MiniMed Group, Inc. (“MiniMed”), announced that an unauthorized third party had accessed data in certain of Medtronic’s information technology (“IT”) systems. In its release, Medtronic disclosed that upon identifying the unauthorized access, it promptly took steps to contain the incident, activated its incident response protocols, and engaged leading external cybersecurity experts to support its inv…

The filing describes the approval of severance pay plans and compensatory arrangements, not the actual departure, appointment, or election of any specific officer or director.

Regulation FD Disclosure On March 18, 2026, MiniMed Group, Inc. (“MiniMed”) announced that the U.S. Food and Drug Administration (the “FDA”) has cleared the MiniMed Flex™, a next-generation discreet, smartphone-controlled insulin pump. The clearance of the MiniMed Flex by the FDA was several months earlier than anticipated, and will facilitate the earlier commercialization of this key MiniMed product. The research and development of the MiniMed Flex was funded in part by affiliates of Blackst…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On January 15, 2026, KH2 entered into a credit agreement which provides for a five-year senior secured revolving credit facility (the “ Revolving Credit Facility ”) in an aggregate principal amount of $500 million to be made available in U.S. dollars and certain approved alternative currencies, initially including Euros, with Citibank, N.A. serving as administrative agent for a s…

Director — Brian Sandstrom: The filing describes the reconstitution of the board following a spin-off/IPO, where the sole director resigned to allow for the appointment of a new nine-member board, which is a standard corporate governance event rather than a loss of a senior executive.

Material Modifications to Rights of Security Holders. The information set forth under

Entry into a Material Definitive Agreement. On March 9, 2026, MiniMed Group, Inc., a Delaware corporation (the “ Company ”), completed its previously announced initial public offering (the “ IPO ”) of 28,000,000 shares of its common stock, par value $0.01 per share (the “ Common Stock ”), at an initial public offering price of $ 20.00 per share. Prior to the IPO, the Company was a wholly owned subsidiary of Medtronic plc, an Irish public limited company (“ Medtronic ”). Prior to and in connec…

Completion of Acquisition or Disposition of Assets. The description of the Company’s merger with KH2 set forth under

Unregistered Sales of Equity Securities. The information set forth under